Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.E. Burton, M.R. Vosko, D.C. Brate.
Comparison of drug dosing methods.
Clin Pharmacokinet, 10 (1985), pp. 1-37
[2.]
L. Aarons.
Population pharmacokinetics: theory and practice.
Br J Clin Pharmacol, 32 (1991), pp. 669-670
[3.]
L.B. Sheiner, B. Rosenberg, V.V. Marathe.
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.
J Pharmacokinet Biopharm, 5 (1977), pp. 445-479
[4.]
L.B. Sheiner.
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
Drug Metab Rev, 15 (1984), pp. 153-171
[5.]
B. Whiting, A.W. Kelman, J. Grevel.
Population pharmacokinetics. Therory and clinical application.
Clin Pharmacokinet, 11 (1986), pp. 387-401
[6.]
T.H. Grasela, E.J. Antal, R.J. Townsend, R.B. Smith.
An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of metodologies.
Clin Pharmacol Ther, 39 (1986), pp. 605-612
[7.]
L. Aarons, S. Vozeh, M. Werk, Weiss, F. Follath.
Population pharmacokinetics of tobramycin.
Br J Clin Pharmacol, 28 (1989), pp. 305-314
[8.]
S.L. Beal, L.B. Sheiner.
University of California, (1989),
[9.]
T.H. Grasela.
Population pharmacokinetics: application to clinical trials.
Pharmacokinetics and pharmacodynamics. Research design and analysis, pp. 85-103
[10.]
L. Aarons.
Software for population pharmacokinetics and pharmacodynamics.
Clin Pharmacokinet, 36 (1999), pp. 255-264
[11.]
J.E. Bennett, J.C. Wakefield.
A comparison of a bayesian population method with two methods as implemented in commercially available software.
J Pharmacokinet Biopharm, 24 (1996), pp. 403-432
[12.]
R. Gomeni, G. Pineau, F. Mentrel.
Population kinetics and conditional assessment of the optimal dosage regimen using P.Pharm software package.
Anticancer Res, 14 (1994), pp. 2.321-2.326
[13.]
A. Schumitzky.
Nonparametric EM algorithms for estimating prior distributions.
Appl Math Computation, 45 (1991), pp. 143-157
[14.]
M. Yasuhara, T. Iga, H. Zenda, K. Okumura, T. Oguma, Y. Yano, et al.
Population pharmacokinetics of vancomycin in japanese adult patients.
Ther Drug Monit, 20 (1998), pp. 139-148
[15.]
O. Lortholary, M. Tod, N. Rizzo, C. Padoin, O. Biard, P. Cassaus, et al.
Population pharmacokinetic study of teicoplanin in severely neutropenic patients.
Antimicrob Ag Chemother, 40 (1996), pp. 1.242-1.247
[16.]
K. Fathinger, S. Vozeh, R. Ha, J. Vlcek, M. Wenk, F. Follath.
Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommedations.
Clin Pharmacol Ther, 50 (1991), pp. 55-56
[17.]
E.M. Parker, M. Hutchison, H. Blumer.
The pharmacokinetics of meropenem in infants and children: a population analysis.
J Antimicrob Chemother, 36 (1995), pp. 63-71
[18.]
R.E. Seay, R.C. Brundage, P.D. Jensen, C.G. Schilling, B.E. Edgren.
Population pharmacokinetics of vancomycin in neonates.
Clin Pharmacol Ther, 56 (1994), pp. 169-175
[19.]
S. Romano, M.M. Fernández de Gatta, M.V. Calvo, D. Caballero, A. Domínguez-Gil, J.M. Lanao.
Population pharmacokinetics of amikacin in patients with haematological malignancies.
J Antimicrob Chemother, 44 (1999), pp. 235-242
[20.]
D.K. Yu, E. Nordborck, Hutchison, E.W. Lewis, W. Sullivan, V.O. Bhargara, et al.
Population pharmacokinetics of teicoplanin in patients with endocarditis.
J Pharmacokinet Biopharm, 23 (1995), pp. 25-39
[21.]
M. Tod, O. Lortholary, D. Seytre, R. Semaoun, B. Uzzan, L. Guillevin, et al.
Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
Antimicrob Ag Chemother, 42 (1998), pp. 849-856
[22.]
G. Lugo, G. Castañeda-Hernández.
Amikacin bayesian forecasting in critically ill patients with sepsis and cirrhosis.
Ther Drug Monitor, 19 (1997), pp. 271-276
[23.]
J. Debord, J.P. Charmes, P. Marquet, L. Merle, G. Lachatre.
Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm.
Int J Clin Pharmacol Ther, 35 (1997), pp. 24-27
[24.]
P. Joubert, F. Bressolle, A. Gouby, P.Y. Douçot, G. Saissi, R. Gomeini.
A population approach to the forecasting of amikacin plasma and urinary levels using a prescribe dosage regimen.
Eur J Drug Metab Pharmacokin, 24 (1999), pp. 39-46
[25.]
S. Romano, M.M. Fernández de Gatta, V. Calvo, E. Méndez, A. Domínguez-Gil, J.M. Lanao.
Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients.
Clin Drug Invest, 15 (1998), pp. 435-444
[26.]
D. Campbell, A.H. Thomson, B. Stack.
Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis.
Ther Drug Monitor, 21 (1999), pp. 281-288
[27.]
M.A. Amantea, R.A. Bowden, A. Forrest, P.K. Working, M.S. Newman, R.D. Mamelok.
The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.
Chemotherapy, 45 (1999), pp. 48-53
[28.]
A.A. Vinks, J.W. Mouton, D.J. Touw, H.G. Heijerman, M. Danhof, W. Bakker.
Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.
Antimicrob Ag Chemother, 40 (1996), pp. 1.091-1.097
[29.]
B. Facca, B. Frame, S. Triesenberg.
Population pharmacokinetics of ceftizoxime administered by continuous infusion in critically ill adult patients.
Antimicrob Ag Chemother, 42 (1998), pp. 1.738-1.787
[30.]
D. Terziivanov, I. Atanasova, V. Dimitrova.
Population pharmacokinetics of ciprofoxacin in patients with liver impairments analyzed by NPEM2 algorithm -a retrospective study.
Int J Clin Pharmacol Ther, 36 (1998), pp. 376-382
[31.]
C.M. Horton, M.N. Dudley, S. Kaul, K.H. Mayer, K. Squires, L. Dunkle, et al.
Population pharmacokinetics of stavudine (D4T) in patients with AIDS or advanced aids-related complex.
Antimicrob Ag Chemother, 39 (1995), pp. 2.309-2.315
[32.]
M.C. Rosario, A.H. Thomson, D.E. Jodrell, C.A. Sharp, H.L. Elliot.
Population pharmacokinetics of gentamicin in patients with cancer.
Br J Clin Pharmacol, 46 (1998), pp. 229-236
[33.]
A. Ortega, A. Aldaz, J. Giraldez, A. Brugarolas.
Population pharmacokinetic parameters of gentamicin in patients with solid tumors: estimation by one-and two-stage methods.
Ther Drug Monitor, 20 (1998), pp. 184-190
[34.]
S. Romano, P. González, P. Tejada, J. Anton, J.M. Aguado, J.M. Lanao.
Influence of diagnostic and treatment factors in the population pharmacokinetics of gentamicin.
J Clin Pharm Ther, 23 (1998), pp. 141-148
[35.]
A.J. McLachlan, S.E. Tett.
Pharmacokinetics of fluconazole in people with HIV infection: a population analysis.
Br J Clin Pharmacol, 41 (1996), pp. 291-298
[36.]
M. Tod, C. Minozzi, G. Beaucaire, D. Ponsonnet, J. Cougnard, O. Petitjean, et al.
Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study.
J Antimicrob Chemother, 44 (1999), pp. 99-108
[37.]
S.L. Preston, G.L. Drusano, A.L. Berman, C.L. Fowler, A.T. Chow, B. Dormseif, et al.
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
Antimicrob Ag Chemother, 42 (1998), pp. 1.098-1.104
[38.]
Y. Tanigawara, H. Nomura, N. Kagimoto, K. Okumura, R. Hori.
Premarketing population pharmacokinetic study of levofloxacin in normal subjetcs and patients with infectious diseases.
Biol Pharm Bull, 18 (1995), pp. 315-320
[39.]
G. Gatti, P. Papa, D. Torre, M. Andreoni, A. Poggio, M. Basetti, et al.
Population pharmacokinetics of rifabutin in human inmunodeficiency virus-infected patients.
Antimicrob Ag Chemother, 42 (1998), pp. 2.017-2.033
[40.]
D.J. Lunn, L. Aarons.
The pharmacokinetics of saquinavir: a Markow Chain Monte Carlo population analysis.
J Pharmacokin Biopharm, 26 (1998), pp. 47-74
[41.]
D.J. Touw, A.A. Vinks, C. Neef.
Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using a nonparametric expectation maximization (NPEM) algorithm.
Pharm World Sci, 19 (1997), pp. 142-151
[42.]
R.W. Jelliffe, P. Gomis, B. Thani, J. Ruskin, F.R. Sattler.
A population pharmacokinetic model of trimethoprim in patients with pneumocystis pneumonia, made with parametric and nonparametric methods.
Ther Drug Monitor, 19 (1997), pp. 450-459
[43.]
M. Izquierdo, J.M. Lanao, L. Cervero, N.V. Jiménez, A. Domínguez-Gil.
A comparative study of the population pharmacokinetics of gentamicin and amikacin in newborn patients.
J Clin Pharm Ther, 18 (1993), pp. 411-413
[44.]
J.H. Botha, J.M. du-Preez, R. Miller, M. Adhikari.
Determination of population pharmacokinetic parameters for amikacin in neonates using mixedeffect models.
Eur J Clin Pharmacol, 53 (1998), pp. 337-341
[45.]
B.G. Charles, Y. Preechagoon, T.C. Lee, P.A. Steer, V.J. Flenady, N. Debuse.
Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants.
J Pharm Sci, 86 (1997), pp. 1.288-1.292
[46.]
P. Karna, C. Lee, A. Kumar.
Population pharmacokinetics of ceftizoxime in premature newborns.
Dev Pharmacol Ther, 20 (1993), pp. 135-143
[47.]
M. Izquierdo, J.M. Lanao, L. Cervero, N.V. Jiménez, A. Domínguez-Gil.
Population pharmacokinetics of gentamicin in premature infants.
Ther Drug Monitor, 14 (1992), pp. 177-183
[48.]
P.D. Jensen, B.E. Edgren, R.C. Brundage.
Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed effect model.
Pharmacotherapy, 12 (1992), pp. 178-182
[49.]
W. Weber, G. Kewitz, K.L. Rost, M. Looby, M. Nitz, L. Harnisch.
Population kinetics of gentamicin in neonates.
Eur J Clin Pharmacol, 44 (1993), pp. 23-25
[50.]
W.F. Dodge, R.W. Jelliffe, C.J. Richardson, R.A. McCleery, J.A. Hokanson, W.R. Snodgrass.
Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method.
Clin Pharmacol Ther, 50 (1991), pp. 25-31
[51.]
W.F. Dodge, R.W. Jelliffe, J.B. Zwischenberger, R.A. Bellanger, J.A. Hokanson, W.R. Snodgrass.
Population pharmacokinetic models: effect of explicit versus assumed constant serum assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation.
Ther Drug Monit, 16 (1994), pp. 552-559
[52.]
M.L. Vervelde, C.M.A. Rademaker, T.G. Krediet, A. Fleer, P. Van-Asten, K.A. Van-Dij.
Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen.
Ther Drug Monitor, 21 (1999), pp. 514-519
[53.]
M. De Hoog, R.C. Schoemaker, J.W. Mouton, J.N. Van der Anker.
Tobramycin population pharmacokinetics in neonates.
Clin Pharmacol Ther, 62 (1997), pp. 392-399
[54.]
C. Grimsley, A.H. Thomson.
Pharmacokinetics and dose requirements of vancomycin in neonates.
Arch Dis Fetal Neonatal Ed, (1999), pp. F221-F227
[55.]
M. Yasuhara, T. Iga, H. Zenda, K. Okumura, T. Oguma, Y. Yano, et al.
Population pharmacokinetics of vancomycin in Japanese pediatric patients.
Ther Drug Monitor, 20 (1998), pp. 612-618
[56.]
M. Mirochnick, E. Capparelli, J. Connor.
Pharmacokinetics of Zidovudine in infants: a population analysis across studies.
Clin Pharmacol Ther, 66 (1999), pp. 16-24
[57.]
L.B. Sheiner, T.H. Grasela.
An introduction to mixed effect modelling: conceps, definitions, and justification.
J Pharmacokinet Biopharm, 19 (1991), pp. 11s-24s
[58.]
L.B. Sheiner, B. Rosenberg, K.L. Melmon.
Modelling of individual pharmacokinetics for computer aided drug dosage.
Comp Biomed Res, 5 (1972), pp. 441-459
[59.]
A.H. Thomson, B. Withing.
Bayesian parameter estimation and population pharmacokinetics.
Clin Pharmacokinet, 22 (1992), pp. 447-467
[60.]
J.C. Eisenanch, S.L. Shafer, B.A. Bucklin, C. Jackson, A. Kallio.
Pharmacokinetics and pharmacodynamics of intraspinal dexmedetomideine in sheep.
Anestesiology, 80 (1994), pp. 1.349-1.359
[61.]
Y. Hashimoto, S. Mori, N. Hama, K. Nakao, H. Imura, M. Yamaguchi, et al.
Nonlinear mixed effect modelling of the pharmacodynamics of natriuretic peptides in rats.
J Pharmacokin Biopharm, 25 (1993), pp. 281-297
[62.]
V. Crosson, E. Fuseau, C. Efhtymiopolus, A. Bye.
Mixed effect modelling of sumatriptan pharmacokinetics during drug development I: interspecies allometric scaling.
J Parmacokinet Biopharm, 25 (1997), pp. 149-167
[63.]
H.G. Schaeffer, G. Ahr, J. Kuhlmann.
Pharmacokinetic development of quinolone antibiotics Int J Clin Pharmacol Ther, 33 (1995), pp. 266-276
[64.]
S.C. Olson.
A population pharmacokinetic profile of imazodan in congestive heart failure patients.
J Pharmacokin Biopharm, 19 (1991), pp. 47s-57s
[65.]
J.B. Fiedler-Kelly, T.H. Grasela, J.C. Fleishaker, C.P. Lewis, A.Q. Sheridan.
Population pharmacokinetic of adinazolam from phase III clinical trials.
Clin Pharmacol Ther, 51 (1992), pp. 158
[66.]
J.P. Lindsay, T.H. Grasela, E.J. Antal, R.L. Miller.
Evaluation of population pharmacokinetics in therapeutic trials: application to postmarketing surveillance.
Clin Pharmacol Ther, 53 (1993), pp. 521-528
[67.]
G. Gatti, C. Brater, M. Murray, N. Sambol.
Analysis of bioequivalence of three generic furosemide products to bran name product using population approach.
Clin Pharmacol Ther, 55 (1994), pp. 195
[68.]
D.A. Graves, I. Chang.
Application of NONMEN to routine bioavailability data.
J Pharmacokin Biopharm, 18 (1990), pp. 145-160
[69.]
N. Kanewa, N. Aoyagi, M. Ogata, M. Ishii.
Application of the NONMEM method to evaluation of the bioavailability of drugs products.
J Pharm Sci, 79 (1990), pp. 1.116-1.120
[70.]
E.J. Antal, T.H. Grasela, L. Eresfesky, B.C. Wells, R.L. Evans, R.B. Smith.
A multi-center study to evaluate the pharmacokinetic and clinical interactions between alprazolam and imipramine.
J Pharmacokinet Biopharm, 19 (1991), pp. 95s-101s
[71.]
P.J. Willians, J. Lane, W. Murray, M.A. Mergener, M. Kamigaki.
Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling.
Clin Pharmacokinet, 22 (1992), pp. 66-74
[72.]
W.B. Gentry, T.K. Henthorn, C.A. Shanks, K.A. Howard, D.K. Gupta, M.J. Avram.
Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
Anestesiology, 81 (1994), pp. 316-324
[73.]
R. Granneman, A. Hsu.
Valproate population pharmacokinetics and pharmacodynamics in patients with migraine headache.
Pharm Res, (1994), pp. 433
[74.]
Z. Hussein, E. Samara, C.S. Locke, M.A. Orchard, G.L. Ringham, G.R. Granneman.
Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis.
Clin Pharmacol Ther, 55 (1994), pp. 441-450
[75.]
J. Shi, N.L. Benowitz, C.P. Derano, L.B. Sheiner.
Population pharmacokineticpharmacodynamic modelling of caffeine: tolerance to pressor effects.
Clin Pharmacol Ther, 51 (1992), pp. 161
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
